CTR20262226 177Lu-NY108 Metastatic castration-resistant prostate cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Turn a newly registered trial into a decision-ready clinical landscape. This report examines CTR20262226 using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, with Drug & Asset MCP and Company & Deal Intelligence MCP used as the companion asset and sponsor enrichment workflow. Explore PatSnap MCP Servers to reproduce the research sequence inside an AI workflow.
MCP evidence snapshot: 23 July 2026. Trial records, recruitment status and projected dates can change after the snapshot and should be rechecked before operational decisions.
Why CTR20262226 is a hot trial to watch
Metastatic castration-resistant prostate cancer is being segmented by mechanism, treatment setting, geography and endpoint architecture. CTR20262226 is notable because it evaluates 177Lu-NY108 in a Phase 2 design sponsored by Norroy Bioscience Co., LTD. The main development question is whether the protocol can translate its rationale into a clinically interpretable and operationally credible readout.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | CTR20262226 |
| Official title | 177Lu-NYM032注射液在PSMA阳性的未接受过紫杉烷类化疗的进展性转移性去势抵抗性前列腺癌（mCRPC）参与者的II期临床研究 |
| Phase / status | Phase 2 / 进行中 （尚未招募） |
| Intervention | 177Lu-NY108 |
| Sponsor | Norroy Bioscience Co., LTD |
| Geography | China |
| Enrollment | [object Object] |
| Primary endpoint | |
| Endpoint time frame | 整个试验周期 |
| Primary completion / readout proxy | Not reported |
Protocol design and endpoint interpretation
The indexed record describes a Phase 2 study of 177Lu-NY108 in Metastatic castration-resistant prostate cancer.
Allocation is 非随机化, masking is 开放, and the intervention model is 单臂试验. Planned enrollment of [object Object] participants across China shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.
- Primary endpoint (整个试验周期) — 评估177Lu-NYM032的有效性：由研究者经前列腺癌临床试验工作组3改良的实体瘤疗效评价标准 v1.1标准判定的进展性PSMA阳性转移性去势抵抗性前列腺癌参与者的影像学无进展生存期和客观缓解率。
Readout outlook and evidence gap
The current protocol points to Not reported as the best available readout proxy. Because this is an active or newly posted study, a trial-specific result citation is not included until a normalized clinical-trial-result record becomes available. That gap is itself operationally important: teams should monitor first result indexing, conference abstracts, protocol amendments and changes to the primary-completion date.
Build a living trial monitor: connect to PatSnap MCP Servers and track recruitment, endpoint revisions, projected readouts and new result records without manually reconciling separate databases.
Asset and sponsor context
Drug & Asset MCP profile: 177Lu-NY108 is indexed as Chemical drugs, Radionuclide Drug Conjugates (RDC), Therapeutic radiopharmaceuticals, with target PSMA, mechanism PSMA inhibitors, and global highest development status Phase 2.
Company & Deal Intelligence MCP profile: Norroy Bioscience Co., LTD did not return an exact normalized organization match in this snapshot. The organization workflow adds identity, location, portfolio and partnering context where available.
The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
- Comparator relevance: evidence against the most decision-relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.
What to monitor next
Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter the probability of success before a headline data release.
Bottom line
CTR20262226 provides a focused lens on Metastatic castration-resistant prostate cancer development. Its value will be determined by whether 177Lu-NY108 can convert the current Phase 2 design into evidence that is clinically meaningful, operationally credible and differentiated from competing programs.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
